Dr. Etminan’s area of research is focused on drug safety. He uses large population-based databases from Canada and the United States as well as epidemiologic methods to quantify adverse drug reactions in the area of ophthalmology as well as other therapeutic areas. He is also interested in causal inference methods and its application in epidemiological research. Recently, Dr. Etminan has recently co-authored a paper looking at the risk of glucagon-like peptide-1 receptor inhibitors, a new class of antidiabetic medications, and risk of diabetic retinopathy. Another area of interest for Dr. Etminan is looking at diabetic outcomes in patients with age related macular degeneration and diabetic macular edema.